$CNST News

Last published 5y ago

5y agoCNST MOR MPSYFMorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-OncologyACCESS NewswireCompany Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG ((FSE:MOR, NASDAQ:MOR) ("MorphoSys") today announced the s
5y agoCNST MOR MPSYFMorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation PharmaceuticalsACCESS NewswireMUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), fo
5y agoCNSTConstellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of PelabresibGlobeNewswireTranslational data support the disease-modifying potential of pelabresib Central pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib treatment observed across a wide range of myelofibro
5y agoCNST ESXB QTS USCRMoore Kuehn Encourages USCR, QTS, CNST and ESXB Investors to Contact Law FirmPR NewswireNEW YORK, June 8, 2021 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shar
5y agoCNSTConstellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual MeetingGlobeNewswirePharmacodynamic data show comprehensive target engagement after treatment with CPI-0209 monotherapy Oral, once-daily 350mg dose selected for Phase 2 Enrollment of tumor-specific expansion cohorts is ongoing CAMBRIDGE, Mass., June 04, 2021 (GLO
5y agoCNST NVCN OEG UONE+1Thinking about buying stock in Constellation Pharmaceuticals, Neovasc, Orbital Energy, Washington Prime Group, or Urban One?PR NewswireNEW YORK, June 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CNST, NVCN, OEG, WPG, and UONE. To s
5y agoCNST MOR MPSYF RPRXMorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty PharmaACCESS NewswireMUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) ("Constellation") wh
5y agoCNST MOR RPRXRoyalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSysGlobeNewswireRoyalty Pharma to provide tailored funding solution to enable MorphoSys' acquisition of Constellation Pharmaceuticals Investment is anchored by royalties on Janssen's Tremfya Partnership also includes royalties on four development-stage therapies, Dev
5y agoCNST MOR RPRXMorphoSys to Acquire Constellation PharmaceuticalsBusiness WireAccelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209 Bolsters Position in Hematology-Oncology and Expands into Solid Tumors Best-in-Class Combined Discovery and Development Capabilitie
5y agoCNSTConstellation Pharmaceuticals to Participate in Jefferies Virtual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 31, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (NASDAQ:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Co
5y agoCNSTConstellation Pharmaceuticals Announces First-Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireDosing underway in the Phase 3 MANIFEST-2 clinical trial Recommended Phase 2 dose determined for CPI-0209 and first patient dosed in the Phase 2 expansion cohorts Upcoming data presentation at ASCO supports the best-in-class target engagement potentia
5y agoCNSTConstellation Pharmaceuticals, Inc. to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 10, 2021 / Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 10, 2021 at 8:00 AM Eastern Time. To listen to the event l
5y agoCNSTConstellation Pharmaceuticals (CNST) Q1 2021 Earnings Call TranscriptEarnings Call TranscriptsCNST earnings call for the period ending March 31, 2021.
5y agoCNSTConstellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2021 ResultsGlobeNewswireCAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM E
5y agoCNSTConstellation Pharmaceuticals (CNST) Q4 2020 Earnings Call TranscriptEarnings Call TranscriptsCNST earnings call for the period ending December 31, 2020.
5y agoCNSTConstellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2020 Financial ResultsGlobeNewswireCAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
5y agoCNSTConstellation Pharmaceuticals to Participate in the 10th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
5y agoCNSTConstellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2020 ResultsGlobeNewswireCAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
5y agoCNSTConstellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial OfficerGlobeNewswireCAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced the appointment of Brendan Delaney to the newly created position of Chief...
5y agoCNSTConstellation Pharmaceuticals to Present at J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Jigar Raythatha, CEO, will present a company overview at the J.P....
5y agoCNSTConstellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH MeetingGlobeNewswire67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeksCPI-0610 demonstrated activity, both as a monotherapy and as add on to...
5y agoCNSTConstellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610 Presented at ASH MeetingGlobeNewswireCAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
6y agoCNSTConstellation Pharmaceuticals Announces Third-Quarter 2020 Financial ResultsGlobeNewswireMANIFEST data update planned for the American Society of Hematology (ASH) meeting in December CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a...
6y agoCNSTConstellation Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2020 ResultsGlobeNewswireCAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
6y agoCNSTConstellation Pharmaceuticals to Participate in Upcoming Virtual Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...
6y agoCNSTConstellation Pharmaceuticals Announces Second-Quarter 2020 Financial Results, Provides Regulatory UpdateGlobeNewswireConstellation has aligned with the FDA on the design of MANIFEST-2, the pivotal Phase 3 clinical trial for CPI-0610 expected to begin in 2H20Constellation plans to explore additional indications for...
6y agoCNSTConstellation Pharmaceuticals to Host Conference Call to Discuss Second Quarter 2020 ResultsGlobeNewswireCAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop...
6y agoCNSTConstellation Pharmaceuticals Announces Pricing of Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
6y agoCNSTConstellation Pharmaceuticals Announces Proposed Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
6y agoJPM AGIO INCY ALXN+4Biotechs Get Wall Street Nod on New Blood Disorder Drugs DataBloombergBiotechnology stocks initially moved higher as Wall Street cheered updates for a range of therapies to treat blood disorders like sickle cell disease and beta thalassemia.
6y agoCNSTConstellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 FranchiseGlobeNewswireSpleen response rates in first-line patients at 12 weeks and 24 weeks in line with previously reported data and differentiated from standard of careSpleen responses demonstrated in...
6y agoCNSTConstellation Pharmaceuticals to Participate in Investor ConferenceGlobeNewswireCAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
6y agoCNSTConstellation Pharmaceuticals to Participate in Investor ConferenceGlobeNewswireCAMBRIDGE, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
6y agoCNSTConstellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610GlobeNewswireCAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
6y agoCNSTConstellation Pharmaceuticals to Participate in Two Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
6y agoCNSTConstellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q4 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
6y agoCNSTConstellation Pharmaceuticals to Present at Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
6y agoCNSTConstellation Pharmaceuticals to Present at J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
6y agoCNSTConstellation Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesGlobeNewswireCAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
6y agoCNSTConstellation Pharmaceuticals Announces Pricing of Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
6y agoCNSTConstellation Pharmaceuticals Announces Proposed Public Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
6y agoCNSTConstellation Pharmaceuticals Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASHGlobeNewswirePreliminary data showed continuing signs of activity across a broad range of parameters, suggesting possible disease-modifying effects of CPI-0610In the first-line treatment arm, 12 out of 15 (80%)...
6y agoCNSTConstellation Pharmaceuticals to Host Analyst/Investor Meeting at ASH to Discuss Updated Preliminary Data from the MANIFEST Clinical Trial with CPI-0610GlobeNewswireCAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
7y agoCNST NNVC AGEN GSK+1Global Nanotechnology and Nanomedicine Treatment Markets Could Reach $350 Billion by 2025PR NewswireResearchers in nanomedicine are making some big-time advances according to reports in various industry journals. Nanomedicine, a relatively new but...
7y agoCNSTConstellation Pharmaceuticals Announces MANIFEST Data Updates Will Be Provided in Oral and Poster Sessions on December 9 at ASHGlobeNewswireCompany will hold investor event on December 9 at 12:30 PM CAMBRIDGE, Mass., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical...
7y agoCNSTConstellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing InvestorsGlobeNewswireCAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
7y agoCNSTConstellation Pharmaceuticals to Present at Cantor Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
7y agoCNSTConstellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 FranchiseGlobeNewswireCAMBRIDGE, Mass., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
7y agoCNSTConstellation Pharmaceuticals to Participate in Two Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
15y agoCNSTConstar International Inc. Receives Delisting Notice from NASDAQ Stock MarketBusiness WirePHILADELPHIA--(BUSINESS WIRE)--Constar International Inc. (NASDAQ: CNST) today announced that on January 11, 2011, the Company was given a notice by The NASDAQ Stock Market that in connection with the Company’s filing of Chapter 11 cases that day, and in accordance with Listing Rules 5101, 5110(b) and IM-5101-1, the NASDAQ staff determined that the Company’s common stock will be delisted from The ...